Merck KGaA, Darmstadt, Germany: Lupus Erythematosus, Systemic trials
The registry lists 12 Lupus Erythematosus, Systemic studies with Merck KGaA, Darmstadt, Germany as lead sponsor. 3 are open to participants now and 5 have results posted.
Phase 1 2Phase 2 7Phase 3 4(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Long-Term Extension (LTE) Study Of Enpatoran In Cutaneous Manifestations Of Lupus With Or Without Systemic Disease [Elowen-LTE]Not yet recruitingNCT07840287Phase 3
- A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)RecruitingNCT07355218Phase 3
- A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic DiseaseRecruitingNCT07332481Phase 3
- The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)CompletedNCT05162586Phase 2Results posted
- A Phase II Study of M2951 in SLETerminatedNCT02975336Phase 2Results posted
- Long-term Safety and Tolerability of Atacicept (Long-term Follow-Up of Participant Who Participated in ADDRESS II)TerminatedNCT02070978Phase 2Results posted
- Efficacy and Safety of Atacicept in Systemic Lupus ErythematosusCompletedNCT01972568Phase 2Results posted
- Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)CompletedNCT00624338Phase 2/3Results posted
- The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)Active, not recruitingNCT05540327Phase 2
- Study of M5049 in CLE and SLE ParticipantsCompletedNCT04647708Phase 1
- MSC2364447C Phase 1b in Systemic Lupus ErythematosusCompletedNCT02537028Phase 1
- Atacicept Demonstrating Dose RESponSeWithdrawnNCT01440231Phase 2